The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls.
5- and 6-Hydroxydopamine, which we had earlier identified as naturally occurring amines in human urine, were quantified in Parkinson's patients treated with L-DOPA, Parkinson's patients whose treatment did not include L-DOPA and in age matched controls. Analysis was carried out by GC-MS of the ditrifluoromethylbenzoyl-trimethylsilyl (DTFMB-TMS) derivatives of the compounds. The concentrations of 5- and 6-hydroxydopamine in the urine of DOPA treated Parkinson's patients were significantly higher than the concentrations from patients not treated and from normal controls. Urinary dopamine levels were greatly elevated in DOPA treated Parkinson's patients while p-tyramine levels were suppressed. No marked differences were seen between the three groups in terms of the urinary concentrations of any of the other amines measured.
Andrew
R
R
Department of Pharmaceutical Sciences, University of Strathclyde, Glasgow.
Watson
D G
DG
Best
S A
SA
Midgley
J M
JM
Wenlong
H
H
Petty
R K
RK
D015306:Biogenic Monoamines / Q000652:urine*; D004298:Dopamine / Q000652:urine; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D006892:Hydroxydopamines / Q000652:urine*; D007980:Levodopa / Q000627:therapeutic use; D009638:Norepinephrine / Q000652:urine; D016627:Oxidopamine / Q000652:urine*; D010300:Parkinson Disease / Q000188:drug therapy / Q000652:urine*; D014439:Tyramine / Q000652:urine
D015306:Biogenic Monoamines; D006892:Hydroxydopamines; C027802:5-hydroxydopamine; D007980:Levodopa; D016627:Oxidopamine; D004298:Dopamine; D009638:Norepinephrine; D014439:Tyramine